TScan Therapeutics (NASDAQ:TCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) issued its quarterly earnings data on Wednesday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02), Zacks reports. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

TScan Therapeutics Trading Down 5.0 %

Shares of TScan Therapeutics stock opened at $1.92 on Thursday. The stock has a market cap of $102.47 million, a P/E ratio of -1.81 and a beta of 0.87. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The business’s 50 day moving average is $2.45 and its 200-day moving average is $4.06. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TCRX shares. Needham & Company LLC lowered their target price on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday. Wedbush restated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.